MedTrace Logo

Candesartan as an Adjunctive Treatment for Bipolar Depression

NCT04430959 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2022-04-27

No results posted yet for this study

Summary

This study will assess the safety and tolerability of Candesartan when used in patients with Bipolar Disorder, in addition to their medication treatment.

Conditions

  • Bipolar Disorder Depression

Interventions

DRUG

Candesartan

Candesartan 4 mg, tablets, orally, once daily for 4 weeks

DRUG

Placebo

Candesartan placebo-matching tablets, orally, once daily for 4 weeks

Sponsors & Collaborators

  • The University of Texas Health Science Center, Houston

    lead OTHER

Principal Investigators

  • Marsal Sanches, MD PhD · University of Texas, Science Center at Houston

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2022-07-01
Completion
2022-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04430959 on ClinicalTrials.gov